Ironwood Pharmaceuticals Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+2.65%
vs ±15.6% implied · ×0.17
shaded = implied · ▲▼ = realized
Ironwood Pharmaceuticals has 3 disclosed suppliers and 6 disclosed customers in SEC filings.
Ironwood Pharmaceuticals Inc
3.49
SentenceIn the third quarter of 2024, we received from COUR the topline data from COUR's Phase II Clinical study for the treatment of PBC.
IRWD 10-Kaccession 0001104659-26-020489
SentenceFor example, we are a party to an amended and restated exclusive license agreement, dated as of December 6, 2016, as amended, by and between GlyPharma Therapeutic Inc. (as predecessor to VectivBio AG) and Ferring, or the Ferring Agreement, pursuant to which we have exclusive rights to apraglutide including an issued composition of matter and method of use patent in the U.S. in lead indications.
IRWD 10-Kaccession 0001104659-26-020489
SentenceWe have strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world, including with AbbVie in the U.S. and all countries worldwide other than China (including Hong Kong and Macau) and Japan, AstraZeneca in China (including Hong Kong and Macau), and Astellas in Japan.
SentenceIn April 2009, we entered into a license agreement with Almirall, S.A., or Almirall, or the European License Agreement, to develop and commercialize linaclotide in Europe (including the Commonwealth of Independent States and Turkey) for the treatment of IBS-C, CIC, and other GI conditions.
IRWD 10-Kaccession 0001104659-26-020489
SentencePursuant to the terms of the development and commercialization agreement with AKP, VectivBio received an upfront payment of JPY 3,000 million ($24.6 million at date of agreement) and development-related payments of JPY 1,600 million in the aggregate ($13.1 million at date of agreement) and is eligible to receive development milestones of JPY 1,000 million ($8.2 million at date of agreement) and up to JPY 19,000 million ($155.8 million at date of agreement) of commercial and sales-based milestone payments.
IRWD 10-Kaccession 0001104659-26-020489
SentenceWe have strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world, including with AbbVie in the U.S. and all countries worldwide other than China (including Hong Kong and Macau) and Japan, AstraZeneca in China (including Hong Kong and Macau), and Astellas in Japan.
IRWD 10-Kaccession 0001104659-26-020489
SentenceUnder the terms of the amended and restated license agreement, Astellas is obligated to pay royalties to us at rates beginning in the mid-single-digits percent and escalating to low-double-digits percent, based on aggregate annual net sales in Japan of products containing linaclotide active pharmaceutical ingredient, or API.
IRWD 10-Kaccession 0001104659-26-020489
Linked news
Expected move
Inputsspot 3.50exp Nov 20ATM strike 2.5ATM straddle 1.27IV 169%